source
- RevMed's Rasonque shows weaker response in common KRAS pancreatic cancer mutation, shares fall over 6%New data from Revolution Medicines indicates that its KRAS inhibitor Rasonque had a reduced response rate in patients whose pancreatic tumors carry the most common KRAS mutation. The subgroup resp…
- CBER Director Karim Mikhail Aims to Restore Stability After Turbulent Leadership ChangesThe FDA's Center for Biologics Evaluation and Research (CBER) is working to regain stability after a period of rapid leadership turnover. Karim Mikhail, who was confirmed as the permanent director…